

Biological Therapies for Cancer: Technologies and Global Markets

Market Research Report | 2025-11-03 | 139 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$4650.00
- 2-5 Users License \$5580.00
- Site License \$6696.00
- Enterprise License \$8035.00

Report description:

Description

Report Scope

This report provides an overview of the global biological therapies for the cancer market and analyzes market trends. It includes global revenue (\$ millions) for the base year data of 2024 and estimated data for the forecast period 2025 through 2030. The market is based on technology, application, end user, and region. The regions covered in this study include North America, Europe, Asia-Pacific, the Rest of the World, focusing on major countries in these regions.

The report also sheds light on developments related to venture capital and corporate investments, regulatory trends, and the enterprise strategies of key firms as well as potential future opportunities stemming from biological therapies for cancer of precision medicine and population genomics programs. The combination of in-depth market forecasts, macroeconomic analysis, and tariff assessments makes this report a critical resource for stakeholders, investors, and policymakers seeking to understand and take advantage of the rapidly developing biological therapies for cancer sector. The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It also analyzes emerging technologies related to the market. The report concludes with an analysis of the competitive landscape, which provides the ranking/share of key players in the biological therapies for cancer market. It also has a dedicated section of company profiles that covers the details of key market players. For market estimates, data have been provided for 2022 and 2023 as the historic years, 2024 as the base year, and 2025-2030 for the forecast years.

Report Includes

- 43 data tables and 53 additional tables
- An analysis of the global markets for biological therapies for cancer treatment and related technologies
- Analyses of the global market trends, with revenue data for 2022-2024, estimates for 2025 and projections of compound annual growth rates (CAGRs) through 2030
- Estimates of the current market size and revenue prospects for the global cancer biologics market, along with a market share analysis by product type, cancer type, and region

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, innovations and standards and the impacts of macroeconomic variables
- Impact analysis of the U.S. tariff laws on the market
- Insights derived from Porter's Five Forces model, as well as global supply chain
- A look at major issues and trends related to the R&D of more effective cancer treatment, new cancer therapeutics in development and the outlook on cancer clinical trials
- Key marketed drugs and recent approvals, sales statistics and past performance of the top-selling biologics and insight into their patent expiries
- A relevant patent analysis, featuring key granted and published patents
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
- Profiles of the leading companies, including Merck & Co. Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., AstraZeneca, and Johnson & Johnson

Executive Summary

Summary:

The global biological therapies market for cancer is expected to grow from \$157 billion in 2025 and is projected to reach \$225 billion by the end of 2030, at a compound annual growth rate (CAGR) of 7.5% during the forecast period of 2025 to 2030.

The biological therapies for cancer market has experienced rapid growth, driven by increasing adoption of targeted and immuno-oncology therapies across multiple tumor types. Rising demand for precision medicine is a key growth factor, as clinicians and healthcare systems prioritize treatments tailored to the molecular and immunological profile of individual patients. Advances in monoclonal antibodies, immune checkpoint inhibitors, CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates (ADCs) are expanding the range of effective treatment options and enabling more durable clinical responses.

Major global players, including Merck & Co., Bristol-Myers Squibb, F. Hoffmann-La Roche, AstraZeneca, Johnson & Johnson, and Novartis, are driving innovation through pipeline expansion, clinical trial programs, and strategic collaborations with hospitals, research institutions, and biotechnology companies. In addition, partnerships between pharmaceutical companies, academic research centers, and government-funded initiatives are accelerating access to cutting-edge biologics and fostering the development of combination therapies.

Table of Contents:

- Table of Contents
- Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Technological Advances
- Market Dynamics and Growth Factors
- Segmental Analysis
- Conclusion
- Chapter 2 Market Overview
- Overview and Market Definition

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Key Modalities and Mechanisms of Action
Porter's Five Forces Model
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential for New Entrants
Competition in the Industry
Threat of Substitutes
Macroeconomic Factors Analysis
Aging Population Driving Cancer Incidence and Demand for Biologics
Rising Healthcare Expenditures and Oncology Drug Spending
Impact of the U.S. Tariff Scenario
Pricing Strategies for Cancer Biologics
Value-Based Pricing
Premium Pricing for Innovation
Indication-Based Pricing
Market Access and Tiered Pricing
Competitive Benchmarking
Cancer Drug Costs
Overview of Biosimilars
Biosimilars and Costs of Cancer Drugs
Biosimilars in India and China
Biosimilars in Europe
Issues with Biosimilars
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Rising Global Cancer Incidence
Advances in Immuno-Oncology and Targeted Therapies
Shift Towards Personalized and Precision Medicine
Market Restraints
High Treatment Costs
Stringent Manufacturing and Regulatory Requirements
Market Opportunities
Expanding Indications for Approved Biologics
Technological Advances in Biologics Manufacturing
Chapter 4 Regulatory Landscape
Biological Therapies for Cancer Industry Regulatory Scenario
Overview
U.S.
EU
Japan
China
India
Medicare Coverage and Reimbursement for Cancer Care
Chapter 5 Emerging Technologies and Developments
Overview
Next-Generation Antibody-Drug Conjugates (ADCs)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Bispecific and Multispecific Antibodies
Neoantigen and Personalized Cancer Vaccines (mRNA and Peptide)
Allogeneic ("Off-the-Shelf") Cell Therapies
Artificial Intelligence (AI) in Biological Cancer Therapies
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis for Biological Therapies for Cancer by Product Type
Monoclonal Antibodies
Vaccines
CAR T-cell Therapy
Cancer Growth Blockers
Immune Checkpoint Inhibitors
Other (Blood Cell Growth Factors, Cytokines)
Market Analysis of Biological Therapies for Cancer by Cancer Type
Epidemiology by Cancer Type/Site
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Other (Blood, Skin, Ovarian, Rare Cancer)
Geographic Breakdown
Global Biosimilars Market by Region
Market Size and Forecast
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Cancer Clinical Trials and Biologics in Development
Overview
Key Pipeline Drugs by Company
Chapter 8 Competitive Landscape
Overview
Biological Therapy for Cancer Market: Major Players
Chapter 9 Appendix
Methodology
References
Abbreviations
Company Profiles
AMGEN INC.
ASTRAZENECA
BAYER AG
BIONTECH SE
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GSK PLC
INCYTE
INNATE PHARMA INC.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

JOHNSON & JOHNSON
LILLY USA LLC
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
SANOFI

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Biological Therapies for Cancer: Technologies and Global Markets

Market Research Report | 2025-11-03 | 139 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4650.00
	2-5 Users License	\$5580.00
	Site License	\$6696.00
	Enterprise License	\$8035.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com